Key Takeaways:
(P1) Clinuvel Pharmaceuticals received final scientific advice from the European Medicines Agency for its pivotal Phase III trial of the drug SCENESSE® as a treatment for vitiligo, with the 300-patient study scheduled to start in the second half of 2026.
(P2) "The dialogue took one year but eventually resulted in a one-off position taken by the Agency, who are now fully across the SCENESSE® program and possible expected outcomes in vitiligo," Dr. Emilie Rodenburger, Clinuvel’s Director of Global Clinical Affairs, said.
(P3) The CUV107 study will use a primary endpoint of T-VASI50, which measures the proportion of patients achieving 50% or more repigmentation on their total body, excluding hands and feet. A key secondary endpoint, F-VASI75, will assess 75% or more repigmentation of the head and neck. The EMA advised that patients with darker skin colors (Fitzpatrick IV-V-VI) should be prioritized.
(P4) The EMA's guidance provides a clearer regulatory path for SCENESSE® in vitiligo, a condition affecting up to 2% of the population with no approved therapies for extensive disease. The agency will use a "totality of evidence" approach, incorporating patient-reported outcomes and photographic evidence, which could support a future marketing authorisation application.
The scientific advice, issued after more than a year of discussions, solidifies the design for the CUV107 study. This trial will compare SCENESSE® combined with narrowband ultraviolet B (NB-UVB) phototherapy against NB-UVB therapy alone.
The EMA's emphasis on a "totality of evidence" means that while the T-VASI50 endpoint is primary, it will not be the sole determinant of efficacy. The evaluation will also heavily weigh patient perspectives, captured through five integrated patient and physician surveys, and photographic evidence of repigmentation. This approach acknowledges the importance of visible changes to patients, particularly for a disease with significant impact on quality of life.
Vitiligo is a skin disorder characterized by the progressive loss of pigment-producing cells, resulting in white patches on the skin. It affects an estimated 0.5% to 2% of the global population. The contrast between affected and unaffected skin is most pronounced in individuals with darker skin tones, making the disease more visible and often increasing the psychosocial burden. The EMA's recommendation to focus on this patient group first acknowledges this unmet need.
SCENESSE® (afamelanotide) is already approved in Europe, the US, Israel, and Australia for preventing phototoxicity in adult patients with erythropoietic protoporphyria (EPP). A successful vitiligo trial would significantly expand the drug's market.
The guidance from the EMA, while non-binding, is a crucial step that reduces regulatory uncertainty for Clinuvel. The company's next major catalyst will be the commencement of the CUV107 study in the latter half of 2026, with investors watching for eventual data on the T-VASI50 and F-VASI75 endpoints.
This article is for informational purposes only and does not constitute investment advice.
